Quantcast

Meningococcal Disease Market Analysis and 2022 Forecasts in New Research Report at RnRMarketResearch.com

May 24, 2013

RnRMarketResearch.com adds Latest Report on “EpiCast Report: Meningococcal Disease — Epidemiology Forecast to 2022” to its store.

Dallas, Texas (PRWEB) May 24, 2013

This report “EpiCast Report: Meningococcal Disease – Epidemiology Forecast to 2022” provides an overview of the risk factors and global trends for meningococcal disease in eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Australia, and Brazil). It includes a 10-year epidemiological forecast of incident cases of meningococcal disease segmented by age (<1, 1—4, 5—14, 15—24, 25—44, 45—64, and 65 years) and serogroup (B, C, Y, and W-135) in these markets. The other serogroups, namely serogroups A and X, are not covered in this analysis because they have very low prevalence in the 8MM and because little data are available for these serogroups. Germany is the only country that had data available for serogroup A, and therefore serogroup A is included in this analysis for Germany. Due to the low incidence of meningococcal disease in Japan, this market was not included in the forecast.

Meningococcal disease is caused by Neisseria meningitidis, which is an encapsulated, Gram-negative bacterium that has an incidence of one to three cases per 100,000 population worldwide (Giuliani et al., 2006). Strains of Neisseria meningitidis are classified based on the chemical composition of unique polysaccharide capsules. Although there are 13 different serogroups, nearly all disease in humans is caused by strains representative of six serogroups: A, B, C, W-135, X and Y (CDC, 2012d; Halperin et al., 2012; Rosenstein et al., 2001). Humans are the only natural reservoir of Neisseria meningitidis, and the bacterium causes three common clinical forms of meningococcal disease: meningitis, blood infection, and pneumonia (CDC, 2012d; Wilder-Smith and Memish, 2003). Up to 10% of adolescents and adults are asymptomatic, transient carriers of the bacterium, which can be transmitted via respiratory droplets or by direct contact (CDC, 2012d).

This report provides an overview of the risk factors and global trends for meningococcal disease in eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Australia, and Brazil). It includes a 10-year epidemiological forecast of incident cases of meningococcal disease segmented by age (<1, 1—4, 5—14, 15—24, 25—44, 45—64, and 65 years) and serogroup (B, C, Y, and W-135) in these markets. The other serogroups, namely serogroups A and X, are not covered in this analysis because they have very low prevalence in the 8MM and because little data are available for these serogroups. Germany is the only country that had data available for serogroup A, and therefore serogroup A is included in this analysis for Germany. Due to the low incidence of meningococcal disease in Japan, this market was not included in the forecast.

Get a copy of this report @ http://www.rnrmarketresearch.com/epicast-report-meningococcal-disease-epidemiology-forecast-to-2022-market-report.html

In 2012, there were 4,665 incident cases of meningococcal disease in the 8MM, and by 2022 the epidemiologists estimate there will be 4,784 incident cases (Annual Growth Rate [AGR]: 0.26%). The US will have the highest AGR at 1.19%, and Germany will have the lowest at negative 0.39%. Although Spain will have a low AGR of 0.01%, by 2022 the market will have the second highest number of incident cases of meningococcal disease (968 incident cases) in the 8MM, following the UK (1,219 incident cases).

During the forecast period, the number of incident cases will remain relatively stable. An increase in international travel to regions of high incidence could cause some serogroups to appear in countries where they were not previously prevalent. In addition to vaccinating international travelers, the vaccination of household members of individuals traveling to high-risk regions would further prevent outbreaks due to strains that certain populations are not yet immune to.

GlobalData epidemiologists obtained surveillance data for each market in this analysis, except for Spain and the UK. However, for these markets a peer-reviewed journal article was used that analyzed the surveillance data in these countries. The surveillance data used in this analysis are collected by country-specific, governmental organizations that routinely collect data on meningococcal disease cases. Use of surveillance data is optimal as it allows for a comprehensive picture of the epidemiology of the disease, including age and serogroup distribution. Although the overall incidence of meningococcal disease is relatively low, the age and serogroup segmentation of incident cases provided in this forecast shows the populations at highest risk for meningococcal disease in each market.

Purchase a copy of this report @ http://www.rnrmarketresearch.com/contacts/purchase?rname=97037

Browse more reports on Therapeutics Market @ http://www.rnrmarketresearch.com/reports/life-sciences/pharmaceuticals/therapeutics

About Us:

RnRMarketResearch.com (http://www.rnrmarketresearch.com/) is an online database of market research reports offers in-depth analysis of over 5000 market segments. The library has syndicated reports by leading market research publishers across the globe and also offer customized market research reports for multiple industries.

For the original version on PRWeb visit: http://www.prweb.com/releases/prwebmeningococcal-disease/market-analysis-report/prweb10767538.htm


Source: prweb



comments powered by Disqus